Nutex Health Q3 revenue $62.7M, up 121% YoY; Adj. EBITDA $1.3M; guides five new hospitals in 2024

Nutex Health Inc.

2023-Q3 EPS reported -$0.02 revenue$177,976,843

Net loss attributable to Nutex Health $(5.5)M; Q3 2022 loss $(412.2)M included $398M goodwill impairment.
Adjusted EBITDA of $1.3M; net cash from operating activities of $2.0M in Q3 2023.
Expects to open five new micro-hospitals in 2024; raised $4.4M from $15M private offering through Nov. 6, 2023.
Appointed Josh DeTillio as COO on Sept 5, 2023; acquired two Florida IPAs with 4,400 managed care patients.
Cash and cash equivalents of $26.8M as of Sept 30, 2023; total assets $479.6M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nutex Health Inc. reported the three months and nine months ended September 30, 2023 results: revenue $62.7 million, net income Net loss attributable to Nutex Health of $(5.5) million in Q3 2023 and $(14.2) million for the first nine months of 2023.

Period: the three months and nine months ended September 30, 2023
Revenue: $62.7 million
Net income: Net loss attributable to Nutex Health of $(5.5) million in Q3 2023 and $(14.2) million for the first nine months of 2023
Result: reported results

Exact text from the filing

is furnished as Exhibit 99.1 to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- NUTEX HEALTH reports THIRd quarter 2023 financial results ● NET revenue of $62.7 million ● NET CASH FROM OPERATING ACTIVITIES OF $2.0 MILLION ● Company expects to open FIVE NEW MICRO-HOPITALS IN 2024 HOUSTON, TX − (PRNewswire) – November 9, 2023 – Nutex Health Inc.

View on SEC.gov

Browse all earnings releases →

Nutex Health Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-018565

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.